Skip to main content

Table 4 Unadjusted and adjusted hazard ratios associated with copeptin levels on short-, mid-, and long-term mortality

From: Risk stratification in emergency patients by copeptin

 

Unadjusted

Adjusteda

hazard ratio (95% CI)

hazard ratio (95% CI)

 

3 months

First year

Total study period

3 months

First year

Total study period

Quartiles

      

Quartile 1 (ref.) <5.2 pmol/L

1

1

1

1

1

1

Quartile 2 5.2-10.5 pmol/L

1.10 (0.47-2.59)

1.33 (0.79-2.24)

1.39 (1.13-1.70)

0.70 (0.29-1.69)

0.87 (0.50-1.50)

1.01 (0.81-1.26)

Quartile 3 10.5-24.1 pmol/L

2.66 (1.28-5.52)

2.53 (1.58-4.04)

2.14 (1.76-2.61)

1.40 (0.66-2.96)

1.27 (0.74-2.08)

1.21 (0.98-1.51)

Quartile 4 >24.1 pmol/L

7.40 (3.80-14.39)

5.62 (3.65-8.66)

3.52 (2.91-4.27)

2.48 (1.19-5.15)

1.95 (1.20-3.17)

1.65 (1.33-2.06)

Elevated copeptin (>11.3 pmol/L)

      

Normal copeptin (ref.)

1

1

1

1

1

1

Elevated copeptin

4.90 (3.08-7.81)

3.61 (2.70-4.85)

2.28 (2.00-2.60)

2.44 (1.47-4.08)

1.85 (1.33-2.58)

1.36 (1.17-1.57)

95%-percentile vs. 5%-percentile

      

5%-percentile (ref.) <2.4 pmol/L

1

1

1

1

1

1

95%-percentile

40.43 (5.51-296.90)

29.36 (7.07-121.99)

5.41 (5.53-8.29)

7.09 (0.92-54.86)

4.99 (1.16-21.50)

1.60 (1.00-2.58)

Per 1 increase in log copeptin

6.66 (4.63-9.57)

4.24 (3.29-5.47)

2.76 (2.41-3.15)

3.24 (2.07-5.08)

1.96 (1.43-2.68)

1.52 (1.29-1.79)

  1. aN-terminal pro-brain natriuretic peptide (log-transformed), gender, age, liver disease, potassium, and hemoglobin remained in the model. CI, confidence interval.